You are here: Industry Insights > Harpoon Therapeutics

News List

Harpoon Therapeutics Doses First Patient with Anti-DLL3 T Cell Engager for Lung Cancer americanpharmaceuticalreview
January 11, 2021
Harpoon Therapeutics announced the first patient has been dosed with HPN328, a delta like ligand 3- (DLL3) targeting TriTAC®, in a Phase 1/2 clinical trial as an investigational treatment of small cell lung cancer (SCLC) and other tumors associated ...
Harpoon Therapeutics Appoints VP, Regulatory Affairs and Quality Assurance contractpharma
August 28, 2020
Harpoon Therapeutics Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, has appointed Karin Ann Thacker, M.Sc., as vice president, regulatory affairs and quality assurance.
CMC Biologics Announces Development and Manufacturing Agreement with Harpoon Therapeutics prnasia
December 14, 2017
CMC ICOS Biologics, a world-leading manufacturer of clinical and commercial therapeutic proteins, and Harpoon Therapeutics, an immunotherapeutic company, use its proprietary TriTAC ™ technology platform to discover and develop new biologics
CMC Biologics Announces Development and Manufacturing Agreement with Harpoon Therapeutics prnasia
December 13, 2017
CMC ICOS Biologics , the world's leading manufacturer of clinical and commercial therapeutic proteins, and immunology oncology firm Harpoon Therapeutics Inc. use its proprietary TriTAC ™ technology platform to discover and develop new biological agents